WASHINGTON (AP) — The Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that don't respond to other treatments.
The drug is called Stivarga and regulators approved it to treat gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved drugs.
The FDA previously approved Stivarga to treat colorectal cancer. It works by blocking several enzymes that promote cancer growth.
The FDA approved the drug for the new use based on a study of nearly 200 patients who were randomly assigned to take Stivarga or a placebo pill.
Patients taking the drug experienced a nearly four month delay in the growth of their tumors compared to taking placebo.
Serious side effects of Stivarga in clinical trials included liver damage, severe bleeding, blistering and peeling of skin, high blood pressure, heart attacks and perforations.
Other drugs approved to treat intestinal tumors include Gleevec, from Novartis, and Sutent, made by Pfizer Inc.
Bayer HealthCare is a subsidiary of Germany's Bayer AG
Planned Parenthood hires forensic analysis firm to debunk 'heavily edited' undercover videos
Small But Honest Columnist Again Forced to Correct Highest-Rated Show on Cable TV | Human Events
Panicky Democratic donors wonder: Are we really going to bet the White House on this shady loser? - Hot Air
Vox "Smart Take" Pushes Gun Confiscation. Here's What Would Happen If They Tried. - Bearing Arms - 2nd Amendment, Gun Confiscation
RIP, the Jeb Bush 2016 Campaign | RedState
Katie Pavlich - Hillary: My Republican Opponents Treat Women Just Like Terrorists Do
Night Watch - Japan Might Finally Be Ready to Join the War on Terror